At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 7,637 enrolled
Drug / intervention
insulin degludec +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events
In Brief
A Phase 3 clinical trial evaluating insulin degludec and insulin glargine for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 7,637 participants across 446 sites in 20 countries.
Detailed Summary
This trial is conducted globally. The aim of this trial is to compare cardiovascular safety of insulin degludec versus insulin glargine in subjects with type 2 diabetes at high risk of cardiovascular events.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesAlgeria, Argentina, Brazil, Canada, Croatia, Greece, India, Italy, Japan, Malaysia, Mexico, Poland, Romania, Russia, South Africa, South Korea, Spain, Thailand, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedOct 2013
Enrollment StartOct 2013
Primary CompletionOct 2016
TodayJul 2026
First PostedOct 10, 2013
Enrollment StartOct 29, 2013
Primary CompletionOct 16, 2016
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 12.7 years ago
Interventions
insulin degludecdrug
Injected once daily subcutaneously (s.c., under the skin)
insulin glarginedrug
Injected once daily subcutaneously (s.c., under the skin)